Rossato P, Glantschnig H, Leidenmühler P, Kopić A, Ruthsatz T, Majer B, Schuster M, Scheiflinger F, & Höllriegl W (2022). Absence of exaggerated pharmacology by recombinant ADAMTS13 in the rat and monkey. Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis 33 (1): 56–60
Glantschnig H, Bauer A, Benamara K, Dockal M, Ehrlich V, Gritsch H, Höbarth G, Horling FM, Kopić A, Reipert B, Rottensteiner H, Ruthsatz T, Schrenk G, Schuster M, Turecek PL, Weber A, Wolfsegger M, Scheiflinger F, Höllriegl W (2019) Evaluation of factor VIII polysialylation: Identification of a longer-acting experimental therapy in mice and monkeys. Journal of Pharmacology and Experimental Therapeutics 371 (1): 95-105
Kopić A, Benamara K, Schuster M, Leidenmühler P, Bauer A, Glantschnig H, Höllriegl W (2019) Coagulation phenotype of wild-type mice on different genetic backgrounds. Laboratory Animals 53 (1): 43-52
Le Besnerais M, Favre J, Denis CV, Mulder P, Martinet J, Nicol L, Levesque H, Veyradier A, Kopić A, Motto DG, Coppo P, Rivhard V, Benhamou Y (2016) Assessment of endothelial damage and cardiac injury in a mouse model mimicking thrombotic thrombocytopenic purpura. Journal of Thrombosis and Haemostasis 14 (10): 1917-30
Kopić A, Benamara K, Piskernik C, Plaimauer B, Horling F, Hoebarth G, Ruthsatz T, Dietrich B, Muchitsch EM, Scheiflinger F, Turecek M, Hoellriegl W (2016) Preclinical assessment of a new recombinant ADAMTS13 drug product (BAX930) to treat thrombotic thrombocytopenic purpura. Journal of Thrombosis and Haemostasis 14 (7): 1410-19
Tersteeg C, Schiviz A, De Meyer SF, Plaimauer B, Scheiflinger F, Rottensteiner H, Vanhoorelbeke K (2015) Potential for recombinant ADAMTS13 as an effective therapy for acquired thrombotic thrombocytopenic purpura. Arteriosclerosis, Thrombosis, and Vascular Biology 35 (11): 2336-42
Plaimauer B, Schiviz A, Kaufmann S, Hoellriegl W, Rottensteiner H, Scheiflinger F (2015) Neutralization of inhibitory antibodies and restoration of therapeutic ADAMTS13 activity levels in inhibitor-treated rats through defined doses of recombinant ADAMTS13. Journal of Thrombosis and Haemostasis 13 (11): 2053-62
Lillicrap D, Schiviz A, Apostol C, Wojciechowski, P, Horling F, Lai CK, Piskernik C, Hoellriegl W, Lollar P (2015) Porcine recombinant factor VIII (Obizur; OBI-1; BAX801): product characteristics and preclinical profile. Haemophilia 22: 308-17
Turecek PL, Abbühl B, Tangada SD, Chapman M, Gritsch H, Rottensteiner H, Schrenk G, Mitterer A, Dietrich B, Höllriegl W, Schiviz A, Horling F, Reipert BM, Muchitsch EM, Pavlova BG, Scheiflinger F (2015) Nonacog agamma, a novel recombinant factor IX with low factor IXa content for treatment and prophylaxis of bleeding episodes. Expert Review of Clinical Pharmacology 8 (2): 163-77
Schiviz A, Magirr D, Leidenmuehler P, Schuster M, Muchitsch EM, Hoellriegl W (2014) Influence of genetic background on bleeding phenotype in the tail-tip bleeding model and recommendations for standardization. Journal of Thrombosis and Haemostasis 12 (11): 1940-2
Lewis KM, Schiviz A, Hedrich HC, Regenbogen J, Goppelt A (2014) Hemostatic efficacy of a novel, PEG-coated collagen pad in clinically relevant animal models. International Journal of Surgery 12 (9): 940-4
Lewis KM, McKee J, Schiviz A, Bauer A, Wolfsegger M, Goppelt A (2014) Randomized, controlled comparison of advanced hemostatic pads in hepatic surgical models. ISRN Surgery 2014: 930803
Dietrich B, Schiviz A, Hoellriegl W, Horling F, Benamara K, Rottensteiner H, Turecek PL, Schwarz HP, Scheiflinger F, Muchitsch EM (2013) Preclinical safety and efficacy of a new recombinant FIX drug product for treatment of hemophilia B. International Journal of Hematology 98 (5): 525-532
Turecek PL, Bossard MJ, Graninger M, Gritsch H, Hoellriegl W, Kaliwoda M, Mathiessen P, Mitterer A, Muchitsch EM, Purtscher M, Rottensteiner H, Schiviz A, Schrenk G, Siekmann J, Varadi K, Riley T, Ehrlich HJ, Schwarz HP, Scheiflinger F (2012) BAX 855, a PEGylated rFVIII product with prolonged half-life. Hämostaseologie 32 (Suppl 1): 29-38
De Meyer SF, Savchenko AS, Haas MS, Schatzberg D, Carrol MC, Schiviz A, Dietrich B, Rottensteiner H, Scheiflinger F, Wagner DD (2012) Protective anti-inflammatory effect of ADAMTS13 on myocardial ischemia/reperfusion injury in mice. Blood 120 (26): 5217-23
Schiviz A, Wuersch K, Piskernik C, Dietrich B, Hoellriegl W, Rottensteiner H, Scheiflinger F, Schwarz HP, Muchitsch EM (2012) A new mouse model mimicking thrombotic thrombocytopenic purpura: correction of symptoms by recombinant human ADAMTS13. Blood 119 (25): 6128-35
Van Helden PM, Unterthurner S, Hermann C, Schuster M, Ahmad RU, Schiviz A, Weiller M, Antoine G, Turecek PL, Muchitsch EM, Schwarz HP, Reipert BM (2011) Maintenance and break of immunological tolerance against human factor VIII in a new transgenic hemophilic mouse model. Blood 118 (13): 3698-307
Pordes AG, Baumgartner CK, Allacher P, Ahmad RU, Weiller M, Schiviz A, Schwarz HP, Reipert BM (2011) T-cell independent restimulation of FVIII-specific murine memory B cells is faciliated by dendritic cells together with toll-like receptor 7 antagonist. Blood 118 (11): 3154-62
Greene T, Schiviz A, Hoellriegl W, Poncz M, Muchitsch EM (2010) Towards a standardization of the murine tail bleeding model. Journal of Thrombosis and Haemostasis 8 (12): 2820-22
Baumgartner B, Jaki T, Wolfsegger MJ, Eder B, Schiviz A, Schwarz HP, Muchitsch EM (2010) Optimization, refinement and reduction of murine in vivo experiments to assess therapeutic approaches for haemophilia A. Laboratory Animal Journal 44 (3): 211-17
Schiviz A, Ruf T, Kübber-Heiss A, Schubert C, Ahnelt PK (2008) Retinal cone topography of artiodactyl mammals: Influence ob body height and habitat. Journal of Comparative Neurology 11; 507 (3): 1336-5
Ahnelt PK, Schubert C, Kübber-Heiss A, Schiviz A, Anger E (2006) Independent variation of retinal S and M cone photoreceptor topographies: a survey of four families of mammals. Visual Neuroscience 2: 1-7
Invited Lecture: Schiviz A, Muchitsch EM, Höllriegl W (2012) Bleeding phenotype of hemophilia A and BALB/c, C57BL/6 & 129S1/Sv mice. presented at the 58th Scientific and Standardization Committee (SSC) of the ISTH, Liverpool, United Kingdom
Lecture: Schiviz A, Lawo JP, Wuersch K, Ehrlich H, Scheiflinger F, Schwarz HP, Höllriegl W, Muchitsch EM (2011) Preclinical Efficacy Testing of Baxter’s Recombinant ADAMTS13 in a Mouse Model of TTP. presented at the XXIII congress of the ISTH, Kyoto, Japan. Abstract: Journal of Thrombosis and Hemostasis 9 (Suppl. 2): 1-970
Lecture: Schiviz A, Resch M, Leidenmühler P, Bischetsrieder B, Schwarz HP, Muchitsch EM (2008) Etablierung der Thrombelastographie bei hämophilen Mäusen zur Diagnose des Gerinnungsstatus von Einzeltieren. presented at the 18. Vetpharmsymposium, Gießen, Germany
First author, presenting author and co-author of various abstracts and posters to be presented at major international conferences to publish preclinical data on the companies’ drug candidates.